Physician

Jennifer B. Lucas, M.D.

According to 2025 Medicare claims, Jennifer Lucas, M.D. (NPI: 1619078979) practices medical oncology in the San Rafael, CA market, with the plurality of this provider's patient population coming from Marin, CA. This provider's primary affiliated billing organization is MARIN CANCER CARE, INC. (NPI: 1629370499; TIN: 272191391) and primary practice location at 94904-2018.

Lucas' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 377 traditional Medicare patients, billed 163,413 HCPCS/CPT codes, and received $2,786,486 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 881 prescription claims across 133 beneficiaries totaling $4,196,225 in drug costs, led by Revlimid (Lenalidomide). DME data shows 29 claims. Open Payments data shows 19 records totaling $154,319. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,557,651 to $2,786,486. Similarly, Part D prescription costs have risen steadily, from $649,334 to $4,196,225. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $3,172 to $743.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	375	106,926	$1,557,651
2016	432	122,199	$1,919,679
2017	375	166,964	$1,986,775
2018	368	90,252	$1,771,567
2019	352	107,103	$2,152,626
2020	300	105,193	$1,858,778
2021	406	111,537	$2,338,705
2022	351	165,640	$2,651,238
2023	352	165,895	$2,687,573
2024	377	163,413	$2,786,486

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	111	734	$649,334
2016	126	932	$1,020,531
2017	128	963	$2,045,608
2018	136	970	$2,789,927
2019	143	997	$2,930,323
2020	129	937	$2,844,125
2021	136	970	$3,113,664
2022	154	1,071	$4,533,148
2023	139	956	$5,609,423
2024	133	881	$4,196,225

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	74	$25,654
2016	N/R	43	$16,781
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	30	$3,473
2020	N/R	11	$210
2021	N/R	79	$4,697
2022	N/R	52	$2,734
2023	N/R	40	$5,676
2024	N/R	29	$801

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	153	335	$148
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	238	458	$100
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	50	61	$73
96372	Injection of drug or substance under skin or into muscle	37	233	$12
J7030	Infusion, normal saline solution , 1000 cc	60	440	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	54	1,512	$947,166
Imbruvica	Ibrutinib	53	1,482	$882,502
Jakafi	Ruxolitinib Phosphate	41	1,230	$691,323
Pomalyst	Pomalidomide	27	756	$552,196
Lenalidomide	Lenalidomide	30	840	$372,744

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	12	$600
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	17	$201

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$71	Celgene Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	16	$154,248	PharmaEssentia USA Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jennifer B. Lucas, M.D.?

Tedicare shows public-source Medicare data for Jennifer B. Lucas, M.D. (NPI 1619078979), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jennifer B. Lucas, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jennifer B. Lucas, M.D.?

Jennifer B. Lucas, M.D. is linked to MARIN CANCER CARE, INC. (billing NPI 1629370499) in the available physician profile data.

Does Jennifer B. Lucas, M.D. have Open Payments data?

Jennifer B. Lucas, M.D. has 19 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.